Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy

Diabetes Care

Volumn 29, Issue 1, 2006, Pages 68-72

  Bril, Vera ^a,c   Buchanan, Robert A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Dainippon Pharmaceuticals   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BROMO 2 FLUOROBENZYL)SPIRO[1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZINE 4,3' PYRROLIDINE] 1,2',3',5' TETRAONE; ALDOSE REDUCTASE INHIBITOR; PLACEBO; RANIRESTAT; UNCLASSIFIED DRUG; ALDEHYDE REDUCTASE; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; PYRAZINE DERIVATIVE; SPIRO COMPOUND; SX 3030;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDIAN NERVE; MOTOR NERVE CONDUCTION; MULTICENTER STUDY; NERVE BIOPSY; NERVE FUNCTION; NERVE POTENTIAL; PERIPHERAL NERVE; PERONEUS NERVE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSORIMOTOR NEUROPATHY; SURAL NERVE; UNSPECIFIED SIDE EFFECT; VIBRATION SENSE; DRUG ANTAGONISM; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOTONEURON; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY;

ALDEHYDE REDUCTASE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MOTOR NEURONS; NEURAL CONDUCTION; PATIENT SELECTION; PERIPHERAL NERVES; PERONEAL NERVE; PLACEBOS; PYRAZINES; SPIRO COMPOUNDS; SURAL NERVE;

EID: 33644876711     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.01.06.dc05-1447     Document Type: Article

References (12)

1. Oates PJ: Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 50:325-392, 2002
2. Gabbay KH, O'Sullivan JB: The sorbitol pathway: enzyme localization and content in normal and diabetic nerve and cord. Diabetes 17:239-243, 1968
3. Bril V, Buchanan RA, the AS-3201 Study Group: Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 27:2369-2375, 2004
4. Bril V, Ono Y, Buchanan RA: Sural nerve sorbitol in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 27:1160-1163, 2004
5. Bril V, Perkins BA: Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 25:2048-2052, 2002
6. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H: Electrophysiological monitoring in clinical trials: Roche Neuropathy Study Group. Muscle Nerve 21:1368-1373, 1998
7. Perkins BA, Olaleye D, Bril V: Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 25:565-569, 2002
8. Arezzo JC: The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Commun 21:13-23, 1997
9. Greene DA, Arezzo JC, Brown MB, the Zenarestat Study Group: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy: Zenarestat Study Group. Neurology 53:580-591, 1999
10. Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, Foyt HL: Natural progression of diabetic peripheral neuropathy in the zenarestat study population. Diabetes Care 27:1153-1159, 2004
11. Laudadio C, Sima AAF: Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial: Ponalrestat Study Group. J Diabetes Complications 12:121-127, 1998
12. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38:869-880, 1995